, because of its ability to inhibit gonadal and adrenal steroidogenesis (6).
Ketoconazole (KTZ), an imidazole derivative able to inhibit cytochrome P-450-dependent enzymatic reac¬ tions (1) , has been used to treat Cushing's syndrome (2, 3) , precocious puberty (4) and prostate carcinoma (5) , because of its ability to inhibit gonadal and adrenal steroidogenesis (6) .
The activity of KTZ is dose dependent, and the drug appears to inhibit selectively 17,20-desmoIase and 17a-hydroxylase when given at doses of 400-600 mg/day (7) . This feature makes KTZ a potentially useful agent in the treatment of non-tumoral hyperandrogenisms, such as polycystic ovarian syndrome (PCOS) or hyperthecosis (8, (9) (10) (11) (12) .
The search for new modes of treatment for these disorders has been driven by the large number of *Present address: Immunobiology Lab., Diabetes Unit, Massachusetts General Hospital, Harvard Medical School, Charleston. MA 02129, USA. patients with these problems, and by the fact that none of the therapeutic options currently available is entirely free of side-effects.
In this report we present the results of a clinical study of the effectiveness of low-dose KTZ treatment for hyperandrogenic conditions generally classified as PCOS (13, 14) , and representing a variety of lesions at adrenal, ovarian and hypothalamic-pituitary sites. The study was designed to assess the hormonal and clinical response to treatment, and the possible complications and side-effects arising from 9 (6) . The increase in the activities of these enzymes in (12) , suggests that the drug acts at both levels. During treatment, E2 increased in our patients, a finding that is at variance with some, but not all, studies on this subject (8, 10, 12 (8) (9) (10) 12) .
